Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E. Ciarimboli G, et al. Among authors: jurgens h. Am J Pathol. 2010 Mar;176(3):1169-80. doi: 10.2353/ajpath.2010.090610. Epub 2010 Jan 28. Am J Pathol. 2010. PMID: 20110413 Free PMC article.
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.
Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jürgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G. Lanvers-Kaminsky C, et al. Among authors: jurgens h. Pharmacogenomics. 2015;16(4):323-32. doi: 10.2217/pgs.14.182. Pharmacogenomics. 2015. PMID: 25823781 Free PMC article.
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Bielack SS, et al. Among authors: jurgens h. J Clin Oncol. 2002 Feb 1;20(3):776-90. doi: 10.1200/JCO.2002.20.3.776. J Clin Oncol. 2002. PMID: 11821461 Clinical Trial.
Prognostic relevance of increased angiogenesis in osteosarcoma.
Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, Jurgens H, Berdel WE, Mesters RM. Kreuter M, et al. Among authors: jurgens h. Clin Cancer Res. 2004 Dec 15;10(24):8531-7. doi: 10.1158/1078-0432.CCR-04-0969. Clin Cancer Res. 2004. PMID: 15623635
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Kempf-Bielack B, et al. Among authors: jurgens h. J Clin Oncol. 2005 Jan 20;23(3):559-68. doi: 10.1200/JCO.2005.04.063. J Clin Oncol. 2005. PMID: 15659502
510 results